Novo Nordisk faces more gloom from price cuts in crowded anti-obesity drugs market
Danish group’s challenges mount despite winning reprieve after Hims & Hers withdraws plan to sell copycat Wegovy pill
Related reading
Novo Nordisk hits out at rival Hims & Hers over cheaper weight-loss pill
US telehealth group will sell product for $49 a month, a third that of its Danish competitor
Hims & Hers abandons copycat weight-loss drug in face of FDA probe
Novo Nordisk had accused the telehealth company of breaching its patent on Wegovy
Novo Nordisk sues Hims & Hers over copycat weight-loss drugs
Shares in US company fall 16% after FDA announces investigation into unregulated medication
Novo Nordisk loses further ground in obesity market
Danish drugmaker expects sales and profit growth at lower end of its guidance this year
Battle for weight-loss supremacy shifts from jabs to pills
Novo Nordisk’s Wegovy tablet offers Danish drugmaker window to win back market share from Eli Lilly
Novo Nordisk shares plunge after profit warning over US weight-loss copycats
Share slide wipes more than €60bn off value of Danish maker of Ozempic and Wegovy